(Q39861100)

15 September 2017

title

A Japanese encephalitis virus vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability (English)

1 reference

Japanese encephalitis virus

15 September 2017

main subject

0 references

1 reference

1 reference

Japanese encephalitis

1 reference

1 reference

Yi-Ling Lin

0 references

Jian-Jong Liang

1 reference

15 September 2017

Ching-Len Liao

series ordinal

1 reference

15 September 2017

Jia-Teh Liao

series ordinal

1 reference

15 September 2017

Yi-Ling Lee

series ordinal

1 reference

15 September 2017

language of work or name

English

0 references

publication date

13 March 2009

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

2746-2754

1 reference

New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Recent advances in Japanese encephalitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Pathogenesis of flavivirus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

7 January 2021

Flavivirus encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Immunopathology of flavivirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Innate and Adaptive Immune Responses Determine Protection against Disseminated Infection by West Nile Encephalitis Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Pathogenesis of West Nile Virus Infection: a Balance between Virulence, Innate and Adaptive Immunity, and Viral Evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Immunological headgear: antiviral immune responses protect against neuroinvasive West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

A Critical Role for Induced IgM in the Protection against West Nile Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Role of CD8+ T cells in control of West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

The host response to West Nile Virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Interferons at age 50: past, current and future impact on biomedicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

7 January 2021

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Inverse interference: how viruses fight the interferon system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Blocking of Interferon-Induced Jak-Stat Signaling by Japanese Encephalitis Virus NS5 through a Protein Tyrosine Phosphatase-Mediated Mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

West Nile virus inhibits the signal transduction pathway of alpha interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Resistance to Alpha/Beta Interferon Is a Determinant of West Nile Virus Replication Fitness and Virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

A highly attenuated strain of Japanese encephalitis virus induces a protective immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Self-cleavage of hepatitis delta virus genomic strand RNA is enhanced under partially denaturing conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Self-cleavage of a 71 nucleotide-long ribozyme derived from hepatitis delta virus genomic RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Generation of deletion and point mutations with one primer in a single cloning step

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Mechanisms of type-I- and type-II-interferon-mediated signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Characterization of the E-138 (Glu/Lys) mutation in Japanese encephalitis virus by using a stable, full-length, infectious cDNA clone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

West Nile virus envelope protein inhibits dsRNA-induced innate immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

A new strategy in design of +RNA virus infectious clones enabling their stable propagation in E. coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Development and Application of a Reverse Genetics System for Japanese Encephalitis Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.007

10.1016/J.VACCINE.2009.03.007

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference